Dr Edward Keystone MD, FRCP, Professor of Medicine, University
of Toronto, Director of the Rebecca MacDonald Centre for Arthritis and
Autoimmune Disease, Mount Sinai Hospital, Canada discussing the effect
of rituximab on radiographic progression in RTA patients and the capability
of rituximab to reduce structural damage in RA patients.
|
Dr Axel Finckh, Rheumatology Division, University of Geneva, Switzerland
comment on the need to monitor patients undergoing rituximab treatment
to identify the optimum time to re-treat thus avoiding a deterioration
of their condition to a pre-rituximab level.
|
Professor Tak, Professor of Medicine, Director, Division of Clinical
Immunology and Rheumatology, EULAR & FOCIS Center of Excellence, Academic
Medical Center, University of Amsterdam, The Netherlands commenting on
:
- the need for an alternative RA treatment for patients who had deteriorated
on other therapies
- the continued use of anti-TNF agents in RA patients
- the positive response achieved with rituximab in patients who had previously
failed on other agents
|
